Andere talen Syndax Pharmaceuticals, Inc.

Aandelen

SNDX

US87164F1057

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 21-06-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
20,05 ^USD	+4,05%		-0,30%	-7,22%

14/06	SSyndax Pharmaceuticals, Inc. Presenteert bijgewerkte positieve gegevens van BEAT AML en Augment-102 Fase 1/2 combinatietests met revumenib bij patiënten met acute leukemieën op het EHA 2024-congres	CI
12/06	Transcript : Syndax Pharmaceuticals, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 08:40 AM

Andere talen

Krijg toegang tot al het nieuws: wees als eerste op de hoogte en reageer voordat de beurs dat doet!

Gratis inschrijven

SSyndax Pharmaceuticals, Inc. Presents Updated Positive Data from BEAT AML and Augment-102 Phase 1/2 Combination Trials of Revumenib in Patients with Acute Leukemias at EHA 2024 Congress	14/06
Syndax Announces Plans to Advance into Phase 1b Portion of Trial Evaluating Revumenib in Relapsed or Refractory Metastatic MSS CRC	07/06
Syndax Pharmaceuticals to Progress into Phase 1b Segment of Revumenib Trial	06/06
Syndax Pharmaceuticals Announces Plans to Advance into Phase 1b Portion of Trial Evaluating Revumenib in Relapsed or Refractory Metastatic MSS CRC	06/06
Syndax Announces Participation at the Goldman Sachs 45th Annual Global Healthcare Conference	05/06
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	03/06
Syndax Pharmaceuticals Appoints Aleksandra Rizo, M.D., Ph.D. to the Board of Directors	15/05
Syndax Pharmaceuticals, Inc. Announces Board Changes	15/05
Syndax Announces Participation at the Bank of America Securities 2024 Health Care Conference	09/05
Syndax Pharmaceuticals Q1 Net Loss Widens	08/05
Syndax Pharmaceuticals : First Quarter 2024 Conference Call	08/05
Syndax: Q1 Earnings Snapshot	08/05
Syndax Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	08/05
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	03/05
Syndax to Announce First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 8, 2024	01/05
Syndax Announces Participation at the Stifel 2024 Virtual Targeted Oncology Forum	10/04
Syndax Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed, Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session	09/04
Syndax Pharmaceuticals, Inc. Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session	08/04
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	05/04
Syndax Pharmaceuticals, Inc. Announces Completion of Enrollment in AUGMENT-101 Pivotal Trial Cohort of Patients with Relapsed/Refractory mNPM1 Acute Myeloid Leukemia	28/03

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Syndax Pharmaceuticals, Inc.

Aandelen

SNDX

US87164F1057

Andere talen

Filters